0001209191-19-061377.txt : 20191219 0001209191-19-061377.hdr.sgml : 20191219 20191219173518 ACCESSION NUMBER: 0001209191-19-061377 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191217 FILED AS OF DATE: 20191219 DATE AS OF CHANGE: 20191219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARLETT CHRISTOPHER A CENTRAL INDEX KEY: 0000897744 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 191296933 MAIL ADDRESS: STREET 1: 100 WILSHIRE BLVD CITY: SANTA MONICA STATE: CA ZIP: 90401 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-17 0 0001645460 Cue Biopharma, Inc. CUE 0000897744 MARLETT CHRISTOPHER A 2425 CEDAR SPRINGS ROAD DALLAS TX 75201 1 0 0 0 Common Stock 2019-12-12 5 J 0 E 1007973 0.00 D 0 I See footnote Common Stock 2019-12-12 5 J 0 E 755980 0.00 A 845582 I See footnote Common Stock 2019-12-17 4 S 0 20732 15.73 D 824850 I See footnote Common Stock 2019-12-19 4 S 0 4000 17.00 D 820850 I See footnote Common Stock 9000 D Pro rata distribution from MDB Capital Group, LLC ("MDB"). The record owner of these securities is MDB. The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes. Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $16.38, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Christopher Marlett by Mark R. Busch, attorney-in-fact 2019-12-19